Keunchil Park, MD; Chong-Jen Yu, MD; Sang-We Kim, MD; et al.
free access
JAMA Oncol. 2016;2(3):305-312. doi:10.1001/jamaoncol.2015.4921
This phase 2, open-label, single-arm study investigates the efficacy of first-line erlotinib therapy in patients with non–small-cell lung cancer with activating EGFR mutations and the use of erlotinib therapy after disease progression.
Adrian G. Sacher, MD; Suzanne E. Dahlberg, PhD; Jennifer Heng, BS; et al.
free access
JAMA Oncol. 2016;2(3):313-320. doi:10.1001/jamaoncol.2015.4482
This cohort study identifies 2237 patients with non–small-cell lung cancer and examines the association between young age at diagnosis and targetable genomic alterations and prognosis.
Mariana Chavez-MacGregor, MD, MSc; Christina A. Clarke, PhD, MPH; Daphne Y. Lichtensztajn, MD, MPH; et al.
free access
has audio
JAMA Oncol. 2016;2(3):322-329. doi:10.1001/jamaoncol.2015.3856
This observational, population-based cohort study monitors time to chemotherapy postsurgery in subgroups of patients with breast cancer and hypothesizes that delaying initiation of adjuvant chemotherapy is associated with adverse outcomes.
-
Audio Author Interview:
Delayed Initiation of Chemotherapy and Breast Cancer (JAMA Oncology)
-
Editorial
Timeliness in Breast Cancer Treatment—The Sooner, the Better
Adrienne G. Waks, MD; Tari A. King, MD; Eric P. Winer, MD
Richard J. Bleicher, MD; Karen Ruth, MS; Elin R. Sigurdson, MD, PhD; et al.
open access
JAMA Oncol. 2016;2(3):330-339. doi:10.1001/jamaoncol.2015.4508
This study of 2 population-based databases of breast cancer from SEER-Medicare and the National Cancer Database compares time to surgery with overall and disease-specific survival.
-
Editorial
Timeliness in Breast Cancer Treatment—The Sooner, the Better
Adrienne G. Waks, MD; Tari A. King, MD; Eric P. Winer, MD
N. Jewel Samadder, MD, MSc, FRCPC; Ken Robert Smith, PhD; Heidi Hanson, PhD; et al.
free access
JAMA Oncol. 2016;2(3):340-346. doi:10.1001/jamaoncol.2015.4265
This nested case-control study of patients in the Utah Cancer Registry who received a diagnosis of cancer of unknown primary site between 1980 and 2010 quantifies the risk of cancer by site in first- and second-degree relatives and first cousins of these individuals.
-
Invited Commentary
Familial Carcinoma of Unknown Primary
Henry T. Lynch, MD; Brody Slostad, BS; Peter Silberstein, MD
Nicholas D. James, BSc, MBBS, PhD, FRCP, FRCR; Melissa R. Spears, MSc, BSc; Noel W. Clarke, MBBS, FRCS(Eng), ChM(Manch), FRCS(Urol); et al.
open access
JAMA Oncol. 2016;2(3):348-357. doi:10.1001/jamaoncol.2015.4350
This study of patients allocated to the control arm of the STAMPEDE Trial explored the survival and the effect on survival of radiotherapy by nodal involvement in high-risk, hormone-naive men with newly diagnosed nonmetastatic prostate cancer starting long-term hormone therapy for the first time.
Benjamin Movsas, MD; Chen Hu, PhD; Jeffrey Sloan, PhD, HSR; et al.
free access
JAMA Oncol. 2016;2(3):359-367. doi:10.1001/jamaoncol.2015.3969
This study uses data from a trial comparing doses of radiation therapy for non–small-cell lung cancer to compare quality of life measures in patients given high vs low radiation doses.